Komori
Fuji Pharma (4554) · InitiativeReframedLatest Changes in Directors and Officers (2026-07-17): "Advanced"

Establishing a Management Foundation to Support Rapid Growth

First written in FY2016-Q3. 12 of 16 entries say "Restated". Latest entry: 2026-07-17.

16entries
11years
1from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2016-Q3 – FY2019-Q3RestatedFY2021 – FY20222016: 120162017: 420172018: 320182019: 320192020: 120202021: 120212022: 120222023: 020232024: 020242025: 120252026: 12026
Same theme, other companies
Strengthening the Management Foundation through Human Capital, In-house DX and GovernanceA theme 11 companies write about · 0 as a headwind · 11 as a tailwind

The whole theme swung hardest in 2025: 3 of 8 companies on the "Worse" side.

8 other companies' latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. 2026-07-17AdvancedChanges in Directors and Officers

    「To further strengthen and accelerate the initiatives under our medium-term management plan, we will reorganize our structure into an organization capable of optimally allocating human resources and capital in line with its implementation.」

    The company has outlined concrete organizational measures to strengthen the management foundation supporting its medium-term management plan, including the optimal allocation of human resources and capital, coordination among corporate planning, human resources, finance, governance and ICT, and the establishment of a new Global Corporate Division.
  2. FY2025-H1ReframedAnnual report

    「To realize Long-Term Vision 2035, we are implementing a medium-term management plan for the next 5 years comprising 4 growth strategies: “expanding our contribution to women’s healthcare,” “expanding our contribution through the biosimilars business,” “profit contribution from the global CMO business,” and “preparing for and identifying the next growth drivers,” together with 3 initiatives to strengthen the management foundation supporting these strategies: “strengthening human resources,” “advancing organizational functions,” and “promoting digitalization.”」

    The management foundation supporting growth has been reorganized from general strengthening of the foundation into “strengthening human resources,” “advancing organizational functions” and “promoting digitalization” to support Long-Term Vision 2035.
  3. FY2022RestatedAnnual report

    「We view as our growth scenario the enhancement of our position in women’s healthcare, a priority area; the transformation of the contrast media business into a sustainable business; the establishment of the biosimilars business; the strengthening of overseas operations; and the establishment of the management foundation supporting these initiatives.」

    The Company continues to pursue the establishment of a management foundation supporting women’s healthcare, contrast media, biosimilars and overseas operations as a growth scenario.
  4. FY2021RestatedAnnual report

    「We view as our growth scenario the enhancement of our position in women’s healthcare, a priority area; the transformation of the contrast media business into a sustainable business; the establishment of the biosimilars business; the strengthening of overseas operations; and the establishment of the management foundation supporting these initiatives.」

    The Company continues its policy of positioning women’s healthcare, contrast media, biosimilars, overseas operations and the management foundation as growth scenarios.
  5. FY2020ReframedAnnual report

    「We view as our growth scenario the enhancement of our position in women’s healthcare, a priority area; the transformation of the contrast media business into a sustainable business; the establishment of the biosimilars business; the strengthening of overseas operations; and the establishment of the management foundation supporting these initiatives.」

    The management foundation supporting growth has been reorganized from general enhancements to management functions into a foundation supporting each growth scenario under the new medium-term plan.
  6. FY2019-Q3RestatedAnnual report

    「Establishing the management foundation for expansion into global markets」

    The Company continues its previous policy of establishing a management foundation supporting growth and overseas expansion.
  7. FY2019-Q2RestatedAnnual report

    「Establishing the management foundation for expansion into global markets」

    The Company continues its previous policy of establishing a management foundation supporting growth and overseas expansion.
  8. FY2019-Q1RestatedAnnual report

    「Establishing the management foundation for expansion into global markets」

    The Company continues its previous policy of establishing a management foundation supporting growth and overseas expansion.
  9. FY2018-Q3RestatedAnnual report

    「Establishing the management foundation for expansion into global markets」

    The Company continues its previous policy of establishing a management foundation supporting growth and overseas expansion.
  10. FY2018-Q2RestatedAnnual report

    「Establishing the management foundation for expansion into global markets」

    The Company continues to pursue its policy of establishing a management foundation supporting growth and overseas expansion.
  11. FY2018-Q1RestatedAnnual report

    「Establishing the management foundation for expansion into global markets」

    It can be confirmed that there have been no significant changes from the previous policy regarding the establishment of a management foundation supporting growth and overseas expansion.
  12. FY2017RestatedAnnual report

    「We will renew our corporate functions, rebuild our business operating structure and create a unique synergistic growth model centered on branded drugs and generics.」

    Continued disclosures on the management foundation supporting growth, including the renewal of corporate functions, restructuring of the business operating framework, and strengthening of financial strategy and IT functions.
  13. FY2017-Q3RestatedAnnual report

    「Establishing the management foundation for expansion into global markets」

    The company continues to document the former challenge of establishing the management foundation for global market expansion.
  14. FY2017-Q2RestatedAnnual report

    「Establishing the management foundation for expansion into global markets」

    The company continues to document the former challenge of establishing the management foundation for global market expansion.
  15. FY2017-Q1RestatedAnnual report

    「Establishing the management foundation for expansion into global markets」

    The former challenge of establishing a management foundation to support rapid growth is now described as establishing the management foundation for global market expansion.
  16. FY2016-Q3First statedAnnual report

    「Establishing a Management Foundation to Support Rapid Growth」

    Establishing the management foundation to support rapid growth is identified as an urgent management priority.
Moved together

"Earnings Pressure from Official Drug Price Cuts" moved the same way as this thread, in the same document, in 2 of its 16 moves.

2222★1234
  1. ★This thread
  2. 1Earnings Pressure from Official Drug Price Cuts2×
  3. 2Building Added Value and Trust Through Fuji Pharma Branding2×
  4. 3Talent development, including specialist knowledge education2×
  5. 4Revenue and profit growth driven by products transferred for sales2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Fuji Pharma yet. It last moved in the Changes in Directors and Officers of 2026-07-17: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Establishing a Management Foundation to Support Rapid Growth | Fuji Pharma Co.,Ltd. (4554) | Komori